MARKET

MDNAF

MDNAF

Medicenna Therapeutics Corp
OTCQX
0.560
+0.002
+0.43%
Opening 09:43 02/13 EST
OPEN
0.560
PREV CLOSE
0.558
HIGH
0.560
LOW
0.560
VOLUME
13.00K
TURNOVER
7.28K
52 WEEK HIGH
1.400
52 WEEK LOW
0.153
MARKET CAP
42.80M
P/E (TTM)
-4.5977
1D
5D
1M
3M
1Y
5Y
1D
Canada's Medicenna narrows Q3 net loss, highlights MDNA11 efficacy
Reuters · 2h ago
MEDICENNA THERAPEUTICS CORP - CASH RUNWAY EXTENDS INTO Q3 2026
Reuters · 2h ago
MEDICENNA THERAPEUTICS Q3 EPS CAD -0.05
Reuters · 2h ago
MEDICENNA THERAPEUTICS REPORTS THIRD QUARTER FISCAL 2026 FINANCIAL RESULTS AND PROVIDES A CORPORATE UPDATE
Reuters · 2h ago
Medicenna Therapeutics appoints Richard Sutin, Angelos Georgakis to board
TipRanks · 3h ago
Medicenna Therapeutics Appoints Richard Sutin and Angelos Georgakis to Board
Reuters · 4h ago
MEDICENNA ANNOUNCES CHANGES TO BOARD COMPOSITION
Reuters · 4h ago
Weekly Report: what happened at MDNAF last week (0202-0206)?
Weekly Report · 4d ago
More
About MDNAF
Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing highly selective versions of IL-2, IL-4 and IL-13 Superkines and first-in-class Empowered Superkines. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.

Webull offers Medicenna Therapeutics Corp stock information, including OTCQX: MDNAF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MDNAF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MDNAF stock methods without spending real money on the virtual paper trading platform.